[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Sharma, P. and Allison, J.P. (2015) The Future of Immune Checkpoint Therapy. Science, 348, 56-61.
https://doi.org/10.1126/science.aaa8172
|
[3]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2019) Up-dated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/JCO.18.00149
|
[4]
|
Durgeau, A., Virk, Y., Corgnac, S., et al. (2018) Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Frontiers in Immunology, 9, Article 14. https://doi.org/10.3389/fimmu.2018.00014
|
[5]
|
Friedman, C.F., Proverbs-Singh, T.A. and Postow, M.A. (2016) Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncology, 2, 1346-1353.
https://doi.org/10.1001/jamaoncol.2016.1051
|
[6]
|
Jain, N., Nguyen, H., Chambers, C., et al. (2010) Dual Function of CTLA-4 in Regulatory T cells and Conventional T Cells to Prevent Multiorgan Autoimmunity. Proceedings of the Na-tional Academy of Sciences of the United States of America, 107, 1524-1528. https://doi.org/10.1073/pnas.0910341107
|
[7]
|
Seidel, J.A., Otsuka, A. and Kabashima, K. (2018) Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in Oncology, 8, Article 86. https://doi.org/10.3389/fonc.2018.00086
|
[8]
|
Martins, F., Sofiya, L., Sykiotis, G.P., et al. (2019) Adverse Ef-fects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance. Nature Reviews Clinical Oncology, 16, 563-580.
https://doi.org/10.3389/fonc.2018.00086
|
[9]
|
Mir, H., Alhussein, M., Alrashidi, S., et al. (2018) Cardiac Compli-cations Associated with Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. The Canadian Journal of Cardiology, 1059-1068.
https://doi.org/10.1016/j.cjca.2018.03.012
|
[10]
|
Drobni, Z.D., Alvi, R.M., Taron, J., et al. (2020) Association be-tween Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque. Circulation, 142, 2299-2311.
https://doi.org/10.1161/CIRCULATIONAHA.120.049981
|
[11]
|
Khunger, A., Battel, L., Wadhawan, A., et al. (2020) New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Current On-cology Reports, 22, Article No. 65.
https://doi.org/10.1007/s11912-020-00925-8
|
[12]
|
Love, V.A., Grabie, N., Duramad, P., et al. (2007) CTLA-4 Ab-lation and Interleukin-12 Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T Lympho-cytes. Circulation Research, 101, 248-257.
https://doi.org/10.1161/CIRCRESAHA.106.147124
|
[13]
|
Wang, J., Okazaki, I.M., Yoshida, T., et al. (2010) PD-1 Deficiency Results in the Development of Fatal Myocarditis in MRL Mice. International Immunology, 22, 443-452. https://doi.org/10.1093/intimm/dxq026
|
[14]
|
Okazaki, T., Tanaka, Y., Nishio, R., et al. (2003) Autoantibodies against Cardiac Troponin I Are Responsible for Dilated Cardiomyopathy in PD-1-Deficient Mice. Nature Medicine, 9, 1477-1483. https://doi.org/10.1038/nm955
|
[15]
|
Johnson, D.B., Balko, J.M., Compton, M.L., et al. (2016) Fulmi-nant Myocarditis with Combination Immune Checkpoint Blockade. The New England Journal of Medicine, 375, 1749-1755. https://doi.org/10.1056/NEJMoa1609214
|
[16]
|
Zou, W., Lu, J. and Hao, Y. (2021) Myocarditis In-duced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. Journal of Inflammation Research, 14, 3077-3088.
https://doi.org/10.2147/JIR.S311616
|
[17]
|
Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. (2018) Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764.
https://doi.org/10.1016/j.jacc.2018.02.037
|
[18]
|
Escudier, M., Cautela, J., Malissen, N., et al. (2017) Clinical Fea-tures, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation, 136, 2085-2087.
https://doi.org/10.1161/CIRCULATIONAHA.117.030571
|
[19]
|
Allenbach, Y., Anquetil, C., Manouchehri, A., et al. (2020) Immune Checkpoint Inhibitor-Induced Myositis, the Earliest and Most Lethal Complication among Rheumatic and Musculoskeletal Toxicities. Autoimmunity Reviews, 19, Article ID: 102586. https://doi.org/10.1016/j.autrev.2020.102586
|
[20]
|
Moslehi, J.J., Salem, J.E., Sosman, J.A., et al. (2018) Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. Lancet, 391, 933. https://doi.org/10.1016/S0140-6736(18)30533-6
|
[21]
|
Lyon, A.R., Yousaf, N., Battisti, N.M.L., et al. (2018) Im-mune Checkpoint Inhibitors and Cardiovascular Toxicity. The Lancet Oncology, 19, e447-e458. https://doi.org/10.1016/S1470-2045(18)30457-1
|
[22]
|
Dal'bo, N., Patel, R., Parikh, R., et al. (2020) Cardiotoxicity of Contemporary Anticancer Immunotherapy. Current Treatment Options in Cardiovascular Medicine, 22, Article No. 62. https://doi.org/10.1007/s11936-020-00867-1
|
[23]
|
Ganatra, S. and Neilan, T.G. (2018) Immune Checkpoint In-hibitor-Associated Myocarditis. The Oncologist, 23, 879-886. https://doi.org/10.1634/theoncologist.2018-0130
|
[24]
|
Awadalla, M., Mahmood, S.S, Groarke, J.D., et al. (2020) Global Longitudinal Strain and Cardiac Events in Patients with Immune Checkpoint Inhibitor-Related Myocarditis. Jour-nal of the American College of Cardiology, 75, 467-478.
https://doi.org/10.1016/j.jacc.2019.11.049
|
[25]
|
Friedrich, M.G., Sechtem, U., Schulz-Menger, J., et al. (2009) Car-diovascular Magnetic Resonance in Myocarditis: A JACC White Paper. Journal of the American College of Cardiology, 53, 1475-1487.
https://doi.org/10.1016/j.jacc.2009.02.007
|
[26]
|
Zhang, L., Awadalla, M., Mahmood, S.S., et al. (2020) Cardiovas-cular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis. European Heart Journal, 41, 1733-1743. https://doi.org/10.1093/eurheartj/ehaa051
|
[27]
|
Nishimura, H., Okazaki, T., Tanaka, Y., et al. (2001) Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice. Science, 291, 319-322. https://doi.org/10.1126/science.291.5502.319
|
[28]
|
Berg, D.D., Vaduganathan, M., Nohria, A., et al. (2017) Im-mune-Related Fulminant Myocarditis in a Patient Receiving Ipilimumab Therapy for Relapsed Chronic Myelomonocytic Leukaemia. European Journal of Heart Failure, 19, 682-685. https://doi.org/10.1002/ejhf.806
|
[29]
|
Zhang, L., Zlo-toff, D.A., Awadalla, M., et al. (2020) Major Adverse Cardiovascular Events and the Timing and Dose of Corticoster-oids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation, 141, 2031-2034.
https://doi.org/10.1161/CIRCULATIONAHA.119.044703
|
[30]
|
Thuny, F., Naidoo, J. and Neilan, T.G. (2022) Cardiovascular Complications of Immune Checkpoint Inhibitors for Cancer. European Heart Journal, 43, 4458-4468. https://doi.org/10.1093/eurheartj/ehac456
|
[31]
|
Pagès, C., Gornet, J.M., Monsel, G., et al. (2013) Ipili-mumab-Induced Acute Severe Colitis Treated by Infliximab. Melanoma Research, 23, 227-230. https://doi.org/10.1097/CMR.0b013e32835fb524
|
[32]
|
Heinzerling, L., Ott, P.A., Hodi, F.S., et al. (2016) Cardio-toxicity Associated with CTLA4 and PD1 Blocking Immunotherapy. Journal for Immunotherapy of Cancer, 4, Article 50. https://doi.org/10.1186/s40425-016-0152-y
|
[33]
|
Tay, R.Y., Blackley, E., Mclean, C., et al. (2017) Successful Use of Equine Anti-Thymocyte Globulin (ATGAM) for Fulminant Myocarditis Secondary to Nivolumab Therapy. Brit-ish Journal of Cancer, 117, 921-924.
https://doi.org/10.1038/bjc.2017.253
|
[34]
|
Agrawal, N., Khunger, A., Vachhani, P., et al. (2019) Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Reports in Oncology, 12, 260-276.
https://doi.org/10.1159/000498985
|
[35]
|
Hu, J.R., Florido, R., Lipson, E.J., et al. (2019) Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors. Cardiovascular Research, 115, 854-868. https://doi.org/10.1093/cvr/cvz026
|
[36]
|
Esfahani, K., Buhlaiga, N., Thébault, P., et al. (2019) Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. The New England Journal of Medicine, 380, 2375-2376. https://doi.org/10.1056/NEJMc1903064
|
[37]
|
Salem, J.E., Allenbach, Y., Vozy, A., et al. (2019) Abatacept for Se-vere Immune Checkpoint Inhibitor-Associated Myocarditis. The New England Journal of Medicine, 380, 2377-2379.
https://doi.org/10.1056/NEJMc1901677
|
[38]
|
Berner, A.M., Sharma, A., Agarwal, S., et al. (2018) Fatal Autoim-mune Myocarditis with Anti-PD-L1 and Tyrosine Kinase Inhibitor Therapy for Renal Cell Cancer. European Journal of Cancer, 101, 287-290.
https://doi.org/10.1016/j.ejca.2018.06.021
|
[39]
|
Guo, X., Wang, H., Zhou, J., et al. (2020) Clinical Manifestation and Management of Immune Checkpoint Inhibitor-Associated Cardiotoxicity. Thoracic Cancer, 11, 475-480.
https://doi.org/10.1111/1759-7714.13250
|